...................... 70 16.4. Dispos ition, Demographics, and Baseline Characteristics ............................. 70 16.5. Primary Efficacy Endpoint and Analysis ................................ ....................... 70 Phase 1b: Safety and Tolerability ................................ ....................... 70 Phase 2: Objective Response Rate (Arm 5 Cohorts A/B) and Progression Free Survival (Arm 6 Cohorts C/D) ............................... 70 16.6. Secondary Efficacy Endpoints and Analyses ................................ ................. 71 Objective Response Rate ................................ ................................ ....71 Overall Survival ................................ ................................ .................. 71 Progression -Free Survival ................................ ................................ ..71 Duration of Response ................................ ................................ ......... 71 Disease Control Rate ................................ ................................ .......... 71 6-month Durable Response Rate ................................ ........................ 72 Heat Biologics, Inc. Viagenpumatucel -L Protocol HS110 -102 CONFIDENTIAL Amendment 6, 24 May 2019 Page 17 of 95 12-month Durable Response Rate ................................ ...................... 72 6-month Overall Survival ................................ ................................ ...72 12-month Overall Survival ................................ ................................ .72 6-month Progression Free Survival ................................ .................... 72 12-month Progression Free Survival ................................ .................. 72 Safety and Tolerability ................................ ................................ .......72 16.7. Exploratory Endpoints and Analyses ................................ .............................. 72 16.8. Safety Analyses ................................ ................................